Arcutis' ZORYVE® (Roflumilast) Cream 0.3% Added to Express Scripts, Inc.® National Formularies in the United States
WESTLAKE VILLAGE, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in immuno-dermatology, today announced that ZORYVE® (roflumilast) cream 0.3% for the treatment of plaque psoriasis in adults and adolescents is now on Express Scripts national formularies for commercial benefit plans, effective November 18. Express Scripts’ commercial national formularies provide access to more than 26 million commercial lives in the United States.
“Ensuring affordable access to ZORYVE is of the utmost priority for Arcutis. The inclusion of ZORYVE on Express Scripts’ national formularies means that our next-generation topical PDE4 inhibitor is now available as a new topical treatment option for millions of adults and adolescents in the United States living with plaque psoriasis,” said Frank Watanabe, President and CEO of Arcutis. “We priced ZORYVE to unlock broad, high-quality access and believe this first major payer formulary acceptance supports our approach. We’re excited by our progress to date and our ability to secure this coverage for ZORYVE with Express Scripts’ national formularies prior to the end of the year. We believe coverage will continue to ramp up as we engage with other payers to further expand commercial formulary access.”
In the Company’s third quarter earnings call, Arcutis reported the signing of this payer agreement. In addition to working with payers, Arcutis is committed to providing affordable access to ZORYVE through responsible pricing, ZORYVE Direct™, a patient access support and saving program†, and the Arcutis Cares™ patient assistance program, which provides ZORYVE at no cost for financially eligible patients who are uninsured or underinsured.‡
ZORYVE is available by prescription only. For more information about ZORYVE visit zoryve.com.
IMPORTANT SAFETY INFORMATION
The most common adverse reactions (=1%) include diarrhea (3%), headache (2%), insomnia (1%), nausea (1%), application site pain (1%), upper respiratory tract infection (1%), and urinary tract infection (1%).
Please see full Prescribing Information.
† Uninsured patients and patients with government insurance are not eligible for the ZORYVE Direct savings program; Other terms and restrictions apply
‡ Subject to financial eligibility requirements. Other terms and restrictions apply
Presentation Theatre Session TBA
Beyond Borders: Growing Your Business across Countries and Continents